Skip to content

Study · Animal study (in vivo) · mouse · 2016

4 results

Treatment with NAD(+) inhibited experimental autoimmune encephalomyelitis by activating AMPK/SIRT1 signaling pathway and modulating Th1/Th17 immune responses in mice.

Wang J, Zhao C, Kong P, Sun H, Sun Z, Bian G, Sun Y, Guo L

International immunopharmacology5 Aug 2016Cited by 44 (Europe PMC)

PMID27500459 (opens in a new tab)DOI10.1016/j.intimp.2016.07.036 (opens in a new tab)PepBankPUB-27500459
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In mice with EAE, NAD+ treatment lessened disease severity.

    In plain wordsIn mice with EAE, NAD+ treatment reduced disease severity.

    Peptide
    NAD+ (nicotinamide adenine dinucleotide)
    Outcome
    DecreaseEAE severity
    Study

    mousen: not reported in source

    C57BL/6 mice with experimental autoimmune encephalomyelitis
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    250mg/kg (body weight) once daily · intraperitonealAs given in this study (mouse).

    Source sentences

    Summary
    We observed that NAD(+) treatment could lessen the severity of EAE.
    2 context sentences
    Summary · context
    In this study, we investigated the effect of NAD(+) administration for the treatment of experimental autoimmune encephalomyelitis (EAE) in C57BL/6 mice.
    Summary · context
    The mice were treated with 250mg/kg (body weight) NAD(+) in PBS administered intraperitoneally once daily.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In mice with EAE, NAD+ treatment attenuated pathological injuries.

    In plain wordsIn mice with EAE, NAD+ treatment reduced tissue injuries.

    Peptide
    NAD+ (nicotinamide adenine dinucleotide)
    Outcome
    DecreasePathological injuries
    Study

    mousen: not reported in source

    C57BL/6 mice with experimental autoimmune encephalomyelitis
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    250mg/kg (body weight) once daily · intraperitonealAs given in this study (mouse).

    Source sentences

    Summary
    Additionally, NAD(+) treatment attenuated pathological injuries of EAE mice.
    2 context sentences
    Summary · context
    In this study, we investigated the effect of NAD(+) administration for the treatment of experimental autoimmune encephalomyelitis (EAE) in C57BL/6 mice.
    Summary · context
    The mice were treated with 250mg/kg (body weight) NAD(+) in PBS administered intraperitoneally once daily.
  3. 03AnimalAnimal study (in vivo)Mechanism

    In mice with EAE, NAD+ treatment activated the AMPK/SIRT1 pathway.

    In plain wordsIn mice with EAE, NAD+ treatment activated the AMPK/SIRT1 pathway.

    Peptide
    NAD+ (nicotinamide adenine dinucleotide)
    Outcome
    IncreaseAMPK/SIRT1 pathway activation
    Study

    mousen: not reported in source

    C57BL/6 mice with experimental autoimmune encephalomyelitis
    Outcome group
    Receptor activity and mechanism · Immune and inflammation
    Studied dose
    250mg/kg (body weight) once daily · intraperitonealAs given in this study (mouse).

    Source sentences

    Summary
    We also found that the AMP-activated protein kinase (AMPK)/silent mating-type information regulation 2 homolog 1(SIRT1) pathway was activated in the NAD(+)-treated mice and NAD(+) treatment suppressed pro-inflammatory T cell responses.
    2 context sentences
    Summary · context
    In this study, we investigated the effect of NAD(+) administration for the treatment of experimental autoimmune encephalomyelitis (EAE) in C57BL/6 mice.
    Summary · context
    The mice were treated with 250mg/kg (body weight) NAD(+) in PBS administered intraperitoneally once daily.
  4. 04AnimalAnimal study (in vivo)Mechanism

    In mice with EAE, NAD+ treatment suppressed pro-inflammatory T cell responses.

    In plain wordsIn mice with EAE, NAD+ treatment reduced inflammatory T cell responses.

    Peptide
    NAD+ (nicotinamide adenine dinucleotide)
    Outcome
    DecreasePro-inflammatory T cell responses
    Study

    mousen: not reported in source

    C57BL/6 mice with experimental autoimmune encephalomyelitis
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    250mg/kg (body weight) once daily · intraperitonealAs given in this study (mouse).

    Source sentences

    Summary
    We also found that the AMP-activated protein kinase (AMPK)/silent mating-type information regulation 2 homolog 1(SIRT1) pathway was activated in the NAD(+)-treated mice and NAD(+) treatment suppressed pro-inflammatory T cell responses.
    2 context sentences
    Summary · context
    In this study, we investigated the effect of NAD(+) administration for the treatment of experimental autoimmune encephalomyelitis (EAE) in C57BL/6 mice.
    Summary · context
    The mice were treated with 250mg/kg (body weight) NAD(+) in PBS administered intraperitoneally once daily.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.